SpeedWeed

JUNE 2, 2021

New Hampshire Governor Chris Sununu (R) just signed a bill to expand the list of qualifying conditions for the state’s medical marijuana program. Researchers have been studying the effects of CBD and other cannabinoids as a potential treatment for autism for years, with positive results. View original article.

Conditions 52

Conditions Programs Research and Development Marijuana 52

LifeCannMD

JULY 15, 2021

Following the 2003 SARS outbreak, symptoms of PTSD emerged in both healthcare workers and those who were under quarantine. CBD and THC, the cannabinoids present in marijuana, influence the body’s own endocannabinoid system which plays an essential role in maintaining homeostasis. A 2015 study authored by Stephanie Yarnell MD, Ph.D.

Cannabinoids 52

Cannabinoids Patients Conditions Events 52

Greencamp

JANUARY 22, 2019

The first thing you should know about the endocannabinoid system is that it’s home to a vast network of cells that have cannabinoid receptors on them. Besides the cells that express cannabinoid receptors, the ECS also includes internal compounds that influence these receptors. Cannabinoids can suppress the immune system.

Cannabinoids 103

Cannabinoids Conditions Patients Strains 103

Medical Cannabis Seedbank

AUGUST 6, 2018

The government implemented a program aimed at granting access to medical cannabis and later modified this to allow cannabis cultivation for medical use. The International Cannabis and Cannabinoids Institute (ICCI) is located in Prague and opened at the end of 2015. 5) Netherlands- slow and steady.

Research and Development 61

Research and Development Cultivation Chronic Pain Cannabis 61

Cannabis Law Report

JUNE 4, 2021

She is Executive Director of the Chacruna Institute for Psychedelic Plant Medicines ([link] [link] She is Public Education and Culture Specialist at the Multidisciplinary Association for Psychedelic Studies (MAPS), and Adjunct Faculty at the East-West Psychology Program at the California Institute of Integral Studies (CIIS). Ian McCall.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

Cannabis Law Report

MARCH 25, 2019

It is worth noting that Marinol ® (dronabinol) is an FDA-approved synthetic cannabinoid that was placed in Schedule III under the CSA in 1999.). 2003, 2004, 2007, 2008, Nov. The DEA has made previous requests–in 2001 and 2006–to the FDA for an evaluation of marijuana. 6059, 6074, 6075, 6077(a), (b), 6253, Nov.

Banking 45

Banking Law Marijuana State Laws 45